Back to Results

ARM Study: A phase II trial to evaluate crizotinib in the neoadjuvant setting in non-small cell lung cancer patients with surgically resectable, ALK, ROS1, or MET-oncogene positive non-small cell lung cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

NSCLC ALK,ROS1 or MET oncogene postive

Phase

II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Type of Study

Treatment

Scope

National

Locations

Lone Tree Medical Center
University of California San Francisco
University of Colorado Hospital

Principal Investigator
Robert Doebele,  MD, PhD

Robert Doebele, MD, PhD

Study ID

Protocol Number: 16-2025

ClinicalTrials.gov: NCT03088930

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers